Appendix D. Table 2Individual Study Quality for the alpha-2-delta ligands trials

StudyAllocation concealmentBlindingIntention-to treat analysesWithdrawals adequately describedQuality
Bogan, 201021UnclearDoubleNo, one subject withdrew consent (<1%)YesFair
Lee, 201118AdequateDouble*No, IRLS score at baseline and at least once during treatment required (4 excluded, 1%)YesGood
Winkelman, 201119AdequateDouble*No, post-baseline data requiredYesGood
Allen, 201020AdequateDoubleYesYesGood
Garcia-Borreguero**, 201022AdequateDoubleYesYesGood
Kushida, 200923UnclearDoubleNo, treatment and post-baseline data required (2 excluded, <1%)YesFair
Garcia-Borreguero, 200224AdequateDoubleNo, treatment required (2 excluded from each phase* 8.3%)YesGood
*

Double blinding denotes participants and investigators;

**

crossover trial.

From: Appendix D, Study Quality/Risk of Bias Tables

Cover of Treatment for Restless Legs Syndrome
Treatment for Restless Legs Syndrome [Internet].
Comparative Effectiveness Reviews, No. 86.
Wilt TJ, MacDonald R, Ouellette J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.